Skip to content
Menu

Eli Lilly Agrees to Buy Calytrix Bio for Up to $1.5 Billion As ObesityWeek Data Roll In

Vandana Singh 22 hours ago

M&ABiotechHealth CareLarge Cap

Eli Lilly agrees to buy Calytrix Bio for up to $1.5 billion and presents new Phase 2 and Phase 3 cardiometabolic data at ObesityWeek 2026.

Eli Lilly and Co. (NYSE:LLY) on Monday agreed to acquire Calytrix Bio Inc. for up to $1.5 billion in cash, as the drugmaker also presents new cardiometabolic data at ObesityWeek 2026 in Washington.

Under the deal terms, Calytrix shareholders stand to receive an upfront cash payment plus additional payments upon meeting clinical and regulatory milestones.

Calytrix develops precision therapies for patients living with myeloproliferative neoplasms (MPNs).

Eli Lilly Wins China Approval for First GLP-1 Weight-Loss Pill, Giving It First-Mover Edge In Potential $4.5 Billion Market: Report

Targeting Disease Drivers in MPNs

Calytrix’s lead investigational biparatopic antibody targets mutant calreticulin-driven essential thrombocythemia and myelofibrosis.

Unlike current drugs that mainly manage symptoms and complications, this candidate aims to deplete disease-driving mutant clones while sparing normal tissues and preserving healthy hematopoiesis.

EloraTZP and Eloralintide Deliver Weight Loss Gains

During the Nov. 14 to 17 conference, Lilly presented clinical results, patient-reported outcomes and real-world evidence across its cardiometabolic portfolio.

In a Nov. 15 Phase 2 session, Lilly’s investigational combination EloraTZP — pairing selective amylin receptor agonist eloralintide with tirzepatide — cut average weight by up to 54.1 pounds, or 23.3%, at 48 weeks from a 232.4-pound baseline in adults with obesity or overweight and type 2 diabetes.

Up to 60% of participants exited the obesity BMI range, while up to 77% reached normal blood sugar levels as average A1C fell by up to 2.9%.

In separate Phase 2 exit interviews, 74% of eloralintide users reported fewer food cravings, especially for sugary foods, and 52% noticed less food noise.

Phase 3 Data for Retatrutide and Zepbound

In another Nov. 15 session, Lilly showcased Phase 3 data for retatrutide, an investigational once-weekly GIP, GLP-1 and glucagon triple hormone receptor agonist.

At 80 weeks across TRIUMPH-1 and TRIUMPH-2, retatrutide reduced sleep apnea breathing disruptions by up to 60.6% and 48.1%, respectively.

Across TRIUMPH-1 and TRIUMPH-4, retatrutide also lowered knee osteoarthritis pain scores by up to 73.1% at 80 weeks and 75.8% at 68 weeks, respectively.

Meanwhile, Zepbound reduced average BMI by 21.4% at 72 weeks in adolescents aged 12 to under 18 with obesity, lifting more than half out of the obesity BMI range.

Real-world survey data also showed 96% to 98% of participants found Lilly’s FDA-approved once-daily oral GLP-1 pill, Foundayo, simple and convenient.

LLY Price Action: Eli Lilly shares were up 1.32% at $1,462.59 at the time of publication Monday, after touching a 52-week high of $1,475.25 earlier in the session, according to Benzinga Pro data.

Photo: Shutterstock

Read at benzinga.com